拉米夫定联合肝立克治疗活动性乙型肝炎肝硬化

Observation of treatment to active hepatitis B and hepato-cirrhosis with lamivudine combined with ganlike

目的 观察拉米夫定联合肝立克治疗活动性肝炎肝硬化的疗效。方法 选择 10 5例活动性乙型肝炎肝硬化病例随机分为Ⅰ组 (拉米夫定 +肝立克 ) 4 0例 ,Ⅱ组 (肝立克 ) 30例 ,Ⅲ组 35例 (拉米夫定 ) ,疗程半年 ,治疗前和治疗后每月检测HA、LN、Pc Ⅲ、ALT、AST、HBV DNA并进行比较。结果 治疗后Ⅰ组各项指标恢复正常的时间明显短于Ⅱ组和Ⅲ组 ,差异有显著意义 (P <0 0 1) ;HBV DNA阴转率Ⅰ组为 6 7 5 % ,Ⅱ组 13 3% ,Ⅲ组 6 2 8% ,Ⅰ组和Ⅲ组明显高于Ⅱ组 (P <0 0 1)。结论 拉米夫定联合肝立克治疗活动性乙型肝炎肝硬化具有协同作用 ,疗效优于单用拉米夫定或肝立克。

Objective To observe the effects of lamivudine combined with ganlike on the treatment of active hepatitis B and hepato-cirrhosis.Methods One handred and five patients suffered from active hepatitis B and hepato-cirrhosis were treated by lamivudine combined with ganlike(n 1=40) for 6 months,and the two control groups were treated by ganlike(n 2=30) or lamivudine(n 3=35) only.HA,LN,Pc-Ⅲ,ALT,AST and HBV-DNA were detected each month,and comparede with the control groups which recepted the general treatment.Results HA,LN,Pc-Ⅲ became normal in the treatment group after 43.5±14.8d and it was 87.5±21.5d or 72.3±18.7d in the control groups(P<0.01,P<0.01).ALT,AST was normal after 36.3±14.7d(treatment group) and 55.8±16.4d or 50.5±12.5d(control group)(P<0.01,P<0.01).HBV-DNA was negative in 67.5% patients in the treatment group,and in 13.3% patients in the control group treated by ganlike and in 62.8% patients treated by lamivudine(P<0.01).Conclusion Lamivudine combined with ganlike were significantly effective in treatment of active hepatitis B and hepato-cirrhosis.